University of Lausanne-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2019

  1. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

    Annals of Oncology